ANDA 218027, held by Sph Zhongxi Pharm. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 218027 (Valganciclovir Hydrochloride), held by Sph Zhongxi Pharm, was first approved by FDA on Apr 16, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE ยท tablet;oral | Valganciclovir Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters